Early Diagnosis and Preventive Therapy in Parkinson’s Disease [electronic resource] /

The premorbid personality of patients with Parkinson’s disease -- Parkinson’s disease: development of dementia in aging -- Psychometric assessment of early signs of dementia in special consideration of Parkinson’s and Alzheimer’s disease — an update -- Sensory and musculo-skeletal dysfunction in Parkinson’s disease—premonitory and permanent -- Autonomic nervous system screening in patients with early Parkinson’s disease -- Clinical and biochemical characteristics of early depression in Parkinson’s disease -- Psychomotor investigations in depressed patients by comparison with Parkinson patients -- Quantitative analysis of voluntary and involuntary motor phenomena in Parkinson’s disease -- Motor performance test -- Measuring body movements in neurological disease, with special reference to Parkinson’s disease -- Long-term measurement of tremor: early diagnostic possibilities -- Tremor and electrically elicited long-latency reflexes in early stages of Parkinson’s disease -- Evoked potentials in Parkinson’s disease -- Brain mapping of EEG and evoked potentials during physiological aging and in Parkinson’s disease, dementia and depression -- Positron emission tomography in Parkinson’s disease glucose metabolism -- Parkinson’s disease studied using PET -- Pathobiochemistry of the extrapyramidal system: a “short note” review -- Dopaminergic neurotransmission and status of brain iron -- Dopaminergic modulation of neuropeptide gene expression in the rat striatum -- The diagnostic relevance of Lewy bodies and other inclusions in Parkinson’s disease -- Cytoskeletal pathology of the Lewy bodies -- Plasma concentrations of endogenous DOPA and 3-O-methyl-DOPA in rats administered benserazide and carbidopa alone or in combination with the reversible COMT inhibitor Ro41-0960 -- Catecholamines in urine, blood and cerebrospinal fluid -- 3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients -- Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro19-6327 -- Aspartate, glutamate, and glutamine in platelets of patients with Parkinson’s disease -- Hypothalamic dysfunction and neuroendocrine research in Parkinson’s disease -- The MPTP model: an update -- Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease? -- Importance of dopaminergic and GABAergic neurones of the nucleus accumbens and the caudate nucleus for motoricity -- Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists? -- Pharmacological and clinical-pharmacological aspects of D1- and D2-receptors -- Chemical modulation of membrane-bound receptors -- Transplantation of dopamine-synthesizing cells — new therapy for Parkinson’s disease? -- L-dopa in Parkinson’s disease -- Pharmacokinetic investigations of various levodopa formulations -- Iron therapy in Parkinson’s disease. Stimulation of endogenous presynaptic L-DOPA biosynthesis by the iron compound oxyferriscorbone -- Provisional experiences with the combination of L-dopa and L-deprenyl -- Clinical pharmacology of amantadine and derivatives -- Dopamine agonist treatment in early Parkinson’s disease -- Subcutaneous apomorphine in Parkinson’s disease -- Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease -- Discussion.

Bibliographic Details

Main Authors:	Przuntek, Horst. editor., Riederer, Peter. editor., SpringerLink (Online service)
Format:	Texto biblioteca
Language:	eng
Published:	Vienna : Springer Vienna, 1989
Subjects:	Medicine., Neurosciences., Pharmacology., Internal medicine., Neurology., Biochemistry., Medicine & Public Health., Internal Medicine., Pharmacology/Toxicology., Biochemistry, general.,
Online Access:	http://dx.doi.org/10.1007/978-3-7091-8994-8
Tags:	Add Tag No Tags, Be the first to tag this record!